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Abstract
Background: Malignant pleural mesothelioma is a rare malignancy. The outcome remains poor
despite complete surgical resection.
Patients and methods: Eleven patients with histologicaly proven epithelial type malignant pleural
mesothelioma undergoing extrapleural pneumonectomy with systemic chemotherapy and/or
radiotherapy before and after surgical resection were retrospectively reviewed.
Results: Ten out of 11 patients underwent complete surgical resection, of these 7 patients had
stage I disease. Of these 7 patients, 5 are alive without any recurrence, a 2-year survival rate of 80%
was observed in this group. There was no operative mortality or morbidity.
Conclusion: Extrapleural pneumonectomy with perioperative adjuvant treatment is safe and
effective procedure for epithelial type malignant pleural mesothelioma.
Introduction
Malignant pleural mesothelioma (MPM) is a relatively
rare entity among intrathoracic malignancies, as com-
pared with lung cancer, although its prevalence has shown
an increase in recent years [1]. Extrapleural pneumonec-
tomy (EPP) is the surgical treatment of choice for MPM
that do not extend in to the mediastinum or on to the
chest wall, although its survival benefit is still not clear
[2]. In a retrospective study of 189 Japanese cases [3],
there were no significant differences in survival at 2-years
between palliative surgery, such as decortication, and EPP
(26% and 30%, respectively). EPP with adjuvant chemo-
therapy and/or radiotherapy has been reported to be effec-
tive against the MPM in its early stages [4,5]. Jaklitsch et
al., [6] advocated that EPP plus postoperative chemother-
apy using paclitaxel and carboplatin with radiotherapy is
effective for MPM if it's of epithelial histology, negative
surgical margin, and if extrapleural lymph nodes are neg-
ative for metastasis. This study reports on resectable
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epithelial type MPM with perioperative treatment consist-
ing of radiation and/or chemotherapy.
Patients and methods
Between 1995 and 2002, 10 patients with epithelial type
MPM underwent EPP with postoperative or preoperative
chemotherapy and/or radiotherapy. The clinical profiles
of these patients are detailed in Table 1. The lesions were
staged by computed tomographic (CT) scan using Inter-
national Mesothelioma Interest Group (IMIG) classifica-
tion. There were 6 stage III, 3 stage II and 1 stage I patient.
A bone scan and Magnetic Resonance Imaging (MRI) of
the brain were performed if metastasis was suspected.
Using the Brigham and Womens Hospital (BWH) staging
system of Sugarbaker et al. [4], after the surgical resection
6 patients were stage I, in terms of having completely
resected primary tumors including chest wall invasion at
the biopsy site.
A standard EPP was performed as described earlier [7].
Following a posterolateral incision, extrapleural space was
entered from the 5th or 6th rib bed, and dissection was car-
ried superiorly toward the apex, antero- and postero-later-
ally, and inferiorly toward the diaphragm. During the
dissection, port site disease at the chest wall was resected
en block. Following an antero-medial pericardiotomy,
hilar vessels were resected using a mechanical stapler, fol-
lowed by resection of the main bronchus. The diaphragm
was divided from the peritoneum, and EPP was com-
pleted. The defects of pericardium and diaphragm were
reconstructed with prosthetic patches. A complete medi-
astinal lymph node dissection was performed in all cases.
In a preoperative adjuvant setting, one course of concur-
rent chemoradiotherapy using cisplatin (CDDP) (80 mg/
m2, on days 1 and 29) with 40 Gy external beam radio-
therapy to the hemithorax [5], was performed in 4
patients (Case 1, 2, 3 and 5) and 2 or 3 courses of chemo-
therapy using CDDP (40 mg/m2 on days 1 and 8), gemcit-
abine (GEM) (800 mg/m2, on days 1 and 8), and
vinorelbine (VNR) (20 mg/m2, on days 1 and 8) were
given at intervals of 3 to 4 weeks in 4 patients (Case 6, 7,
8 and 11) (Table 1). Three patients received 2 courses of
postoperative chemotherapy using CDDP (80 mg/m2, on
day 1 and 8), GEM (800 mg/m2 on days 8 and 15) and
UFT (tegafur/uracil) (400 mg/m2 postoperative on days
1–15) with 3 to 4 weeks interval (Case 4, 9 and 10) (Table
1). One patient received 50 Gy postoperative radiation to
the previous thoracic drainage site (Case 10).
Results
Postoperative course of the patients were uneventful, and
no morbidity or mortality was experienced. Six patients
experienced a relapse in the thorax. One patient under-
went resection of the chest wall for recurrence at 12
months after EPP. Other 5 patients (Case 5, 6, 8, 9 and 11)
are surviving without any disease. All the survivors had
BWH stage I disease, which showed an 80%, 2-year sur-
vival. The survival in 4 patients with BWH stage II-III dis-
ease was 37% at 2-year. Postoperative chemotherapy was
started 2 to 3 months after surgery, and grade 4 neutrope-
nia was observed in all 3 cases, while grade 3 loss of appe-
tite was observed in one. Of the 3 patients who underwent
preoperative chemotherapy, a reduction in size of the
tumors by 18 to 74% was seen following chemotherapy
(Figure 1). Pathological examination of the resected spec-
imens in all 3 cases showed extensive fibrosis with only a
small focus of tumor cells (Figure 2). In Case 10, an
exploratory thoracotomy was done for suspected recur-
rence, however, the intrathoracic lesion was found to be a
herniated liver from the defect of the reconstructed
diaphragm.
Table 1: Clinical summary
Case IMIG stage BWH stage Resection Adjuvant therapy Recurrence Survival status/months
1 49 F III(T3N2M0) III Complete Pre CDDP/Hemithorax RTx Pericardium Died 22
2 63 M III(T3N2M0) III Complete Pre CDDP/Hemithorax RTx Ipsilateral thorax Died 30
3 61 M III(T3N2M0) III Incomplete Pre CDDP/Hemithorax RTx Ipsilateral thorax Died 1
4 59 F III(T1N2M0) III Complete Post CDDP/GEM/UFT Lung Dead 28
5 58 M II(T2N0M0) I Complete Pre CDDP/Hemithorax RTx None Alive 28
6 50 M II(T2N0M0) I Complete Pre CDDP/GEM/VNR Ipsilateral thorax Alive 35
7 55 M II(T2N0M0) I Complete Pre CDDP/GEM/VNR Pericardium Died 6
8 66 M III(T3N0M0) I Complete Pre CDDP/GEM/VNR None Alive 15
9 48 M III(T3N0M0) I Complete Post CDDP/GEM/UFT None Alive 32
10 57 M I(T1N0M0) I Complete Post CDDP/GEM/UFT None Alive 39
12 58 M I(T1N0M0) I Complete Pre CDDP/GEM/VNR None Alive 12
IMIG – International mesothelioma Interest group; BWH – Brigham and Women's Hospital; F – Female; M – male; Pre – Pre Operative; Post – Post 
operativ; CDDP – Cisplatin; RTx – Radiotherapy; GEM – gemcitabine; VNR – Vinorelbine; UFT – Uracil/tegafurWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/11
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Discussion
Early stage MPM, especially of the epithelial type, is a dis-
ease localized to the hemithorax. Therefore, EPP with or
without perioperative adjuvant therapy should be effec-
tive, as is shown previously. Sugarbaker et al., [4] reported
that the treatment with EPP and adjuvant chemotherapy
and hemithorax radiotherapy is effective for select
patients with MPM. Nearly 50% of the cases who undergo
complete resection of epithelial type MPM survive at 5
years. Rusch et al., [5] showed favorable results with EPP
followed by radiation. Survival rate at 5-years for patients
with stage I/II IMIG classification was 40% [5].
The aim of the perioperative adjuvant therapy is to control
tumor cells located at the front line and the lymphatic sys-
tem and to sterilize the margin of EPP. However, a thera-
peutically active modality must be considered from the
standpoint of patient benefit and safety. The mortality
rates for EPP reported in literature are 3.8% by Sugarbaker
et al., [4] and 7.9% by Rusch et al., [5]. In our series, all
patients returned to active social life following their treat-
ment, indicating that EPP with perioperative adjuvant
therapy is well tolerated. Complete resection of capsu-
lated MPM was achieved in 6 cases that had been desig-
nated as BWH stage I. Interestingly, as shown in table 1,
BWH stage predicted the prognosis well however IMIG
stage failed to do so. This indicated that local therapy for
epithelial type MPM might be crucial for staging and prog-
nosis as well.
Sugarbaker et al., [4] started chemotherapy using carbopl-
atin and paclitaxel within 4 weeks after EPP. In our series,
chemotherapy was started 2 months after EPP in 4
patients who received CDDP/GEM/UFT. Of the 3 patients
The effect of preoperative chemotherapy using CDDP/GEM/VNR in Case 5: Chest CT before (a, b) and after chemotherapy (c,  d) Figure 1
The effect of preoperative chemotherapy using CDDP/GEM/VNR in Case 5: Chest CT before (a, b) and after chemotherapy (c, 
d). The size of the primary tumors, measured two-dimensionally (arrows) decreased by 74% after chemotherapy.World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/11
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receiving preoperative chemotherapy using CDDP/GEM/
VNR, 2 patients received 2 courses and the other received
3 courses. EPP was performed within 5 weeks after
cessation of chemotherapy. The clinical and pathological
effects were remarkable. Among chemotherapeutic
agents, GEM [8] and VNR [9] are reported to be active and
the combination of them with CDDP was used in our
study. Neutropenia was the main adverse effect of this reg-
imen observed, which reversed with G-CSF. We therefore
suggest that preoperative chemotherapy using such active
agents followed by EPP is effective and safe procedure.
However, this needs to be tested in a randomized control-
led trial.
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Photomicrograph of case number 5 showing the effect of preoperative chemotherapy Figure 2
Photomicrograph of case number 5 showing the effect of preoperative chemotherapy. A). Histology of pretreatment biopsy 
and resected specimen in the above case (× 400, hematoxylin and eosin) B.) Only a small focus of epithelial type mesothelioma 
cells was found in the resected specimen.